Literature DB >> 27815703

Development of an activity disease score in patients with uveitis (UVEDAI).

Esperanza Pato1, Mª Auxiliadora Martin-Martinez2, Adela Castelló3, Rosalía Méndez-Fernandez4,5, Santiago Muñoz-Fernández6, Miguel Cordero-Coma7, Lucia Martinez-Costa8, Elia Valls9, Miguel Reyes10, Félix Francisco11, Mar Esteban12, Alex Fonollosa13, Fernando Sanchez-Alonso2, Cruz Fernández-Espartero14, Teresa Diaz-Valle15, José Miguel Carrasco16, Emma Beltran-Catalán17, Marisa Hernández-Garfella18, María Victoria Hernández19, Laura Pelegrin20, Ricardo Blanco21, David Diaz-Valle4,5.   

Abstract

To develop a disease activity index for patients with uveitis (UVEDAI) encompassing the relevant domains of disease activity considered important among experts in this field. The steps for designing UVEDAI were: (a) Defining the construct and establishing the domains through a formal judgment of experts, (b) A two-round Delphi study with a panel of 15 experts to determine the relevant items, (c) Selection of items: A logistic regression model was developed that set ocular inflammatory activity as the dependent variable. The construct "uveitis inflammatory activity" was defined as any intraocular inflammation that included external structures (cornea) in addition to uvea. Seven domains and 15 items were identified: best-corrected visual acuity, inflammation of the anterior chamber (anterior chamber cells, hypopyon, the presence of fibrin, active posterior keratic precipitates and iris nodules), intraocular pressure, inflammation of the vitreous cavity (vitreous haze, snowballs and snowbanks), central macular edema, inflammation of the posterior pole (the presence and number of choroidal/retinal lesions, vascular inflammation and papillitis), and global assessment from both (patient and physician). From all the variables studied in the multivariate model, anterior chamber cell grade, vitreous haze, central macular edema, inflammatory vessel sheathing, papillitis, choroidal/retinal lesions and patient evaluation were included in UVEDAI. UVEDAI is an index designed to assess the global ocular inflammatory activity in patients with uveitis. It might prove worthwhile to motorize the activity of this extraarticular manifestation of some rheumatic diseases.

Entities:  

Keywords:  Activity index; Ocular inflammation; Outcome measures; Uveitis

Mesh:

Year:  2016        PMID: 27815703      PMCID: PMC5357298          DOI: 10.1007/s00296-016-3593-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  35 in total

1.  Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center.

Authors:  B Bodaghi; N Cassoux; B Wechsler; D Hannouche; C Fardeau; T Papo; D L Huong; J C Piette; P LeHoang
Journal:  Medicine (Baltimore)       Date:  2001-07       Impact factor: 1.889

2.  Impact of macular edema on visual acuity in uveitis.

Authors:  Charlotte W T A Lardenoye; Bram van Kooij; Aniki Rothova
Journal:  Ophthalmology       Date:  2006-08       Impact factor: 12.079

3.  Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.

Authors:  Andrew D Dick; Ilknur Tugal-Tutkun; Stephen Foster; Manfred Zierhut; S H Melissa Liew; Vladimir Bezlyak; Sofia Androudi
Journal:  Ophthalmology       Date:  2013-01-03       Impact factor: 12.079

Review 4.  Role of OCT in the diagnosis and management of macular edema from uveitis.

Authors:  Rebecca S Hunter; Dimitra Skondra; George Papaliodis; Lucia Sobrin
Journal:  Semin Ophthalmol       Date:  2012 Sep-Nov       Impact factor: 1.975

Review 5.  Understanding uveitis: the impact of research on visual outcomes.

Authors:  Marc D de Smet; Simon R J Taylor; Bahram Bodaghi; Elisabetta Miserocchi; Philip I Murray; Uwe Pleyer; Manfred Zierhut; Talin Barisani-Asenbauer; Phuc LeHoang; Sue Lightman
Journal:  Prog Retin Eye Res       Date:  2011-07-22       Impact factor: 21.198

Review 6.  Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis.

Authors:  Esperanza Pato; Santiago Muñoz-Fernández; Félix Francisco; Miguel A Abad; Jesús Maese; Ana Ortiz; Loreto Carmona
Journal:  Semin Arthritis Rheum       Date:  2010-07-24       Impact factor: 5.532

7.  Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience.

Authors:  Elisabetta Miserocchi; Stefanos Baltatzis; Anthony Ekong; Manolette Roque; C Stephen Foster
Journal:  Ophthalmology       Date:  2002-01       Impact factor: 12.079

8.  Quantitative analysis of peripheral vasculitis, ischemia, and vascular leakage in uveitis using ultra-widefield fluorescein angiography.

Authors:  Michael Karampelas; Dawn A Sim; Colin Chu; Ester Carreno; Pearse A Keane; Javier Zarranz-Ventura; Mark Westcott; Richard W J Lee; Carlos E Pavesio
Journal:  Am J Ophthalmol       Date:  2015-02-21       Impact factor: 5.258

Review 9.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

10.  OMERACT: an international initiative to improve outcome measurement in rheumatology.

Authors:  Peter Tugwell; Maarten Boers; Peter Brooks; Lee Simon; Vibeke Strand; Leanne Idzerda
Journal:  Trials       Date:  2007-11-26       Impact factor: 2.279

View more
  2 in total

1.  Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC).

Authors:  Ivan Foeldvari; Jens Klotsche; Gabriele Simonini; Clive Edelsten; Sheila T Angeles-Han; Regitze Bangsgaard; Joke de Boer; Gabriele Brumm; Rosa Bou Torrent; Tamas Constantin; Cinzia DeLibero; Jesus Diaz; Valeria Maria Gerloni; Margarida Guedes; Arnd Heiligenhaus; Kaisu Kotaniemi; Sanna Leinonen; Kirsten Minden; Vasco Miranda; Elisabetta Miserocchi; Susan Nielsen; Martina Niewerth; Irene Pontikaki; Carmen Garcia de Vicuna; Carla Zilhao; Steven Yeh; Jordi Anton
Journal:  Pediatr Rheumatol Online J       Date:  2019-10-01       Impact factor: 3.054

2.  A Network of Serum Proteins Predict the Need for Systemic Immunomodulatory Therapy at Diagnosis in Noninfectious Uveitis.

Authors:  Jonas J W Kuiper; Fleurieke H Verhagen; Sanne Hiddingh; Roos A W Wennink; Anna M Hansen; Kerry A Casey; Imo E Hoefer; Saskia Haitjema; Julia Drylewicz; Mehmet Yakin; H Nida Sen; Timothy R D J Radstake; Joke H de Boer
Journal:  Ophthalmol Sci       Date:  2022-05-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.